Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Cardiac toxicity induced by anticancer therapy is of considerable concern for, once it develops, it may compromise the clinical effectiveness of treatment independent of the oncologic prognosis. The main strategy to minimize cardiotoxicity is to detect high-risk patients and begin prophylactic treat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giulia Bacchiani, Daniela Cardinale
Formato:	article
Lenguaje:	EN
Publicado:	South African Heart Association 2017
Materias:	cardiac toxicity biomarkers early prophylactic treatment cancer chemotherapy Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/12f648ef49e640cfa4136c500eecbf4d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:12f648ef49e640cfa4136c500eecbf4d
record_format	dspace
spelling	oai:doaj.org-article:12f648ef49e640cfa4136c500eecbf4d2021-11-29T13:06:37ZUsing biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy10.24170/9-4-18281996-67412071-4602https://doaj.org/article/12f648ef49e640cfa4136c500eecbf4d2017-04-01T00:00:00Zhttps://www.journals.ac.za/index.php/SAHJ/article/view/1828https://doaj.org/toc/1996-6741https://doaj.org/toc/2071-4602Cardiac toxicity induced by anticancer therapy is of considerable concern for, once it develops, it may compromise the clinical effectiveness of treatment independent of the oncologic prognosis. The main strategy to minimize cardiotoxicity is to detect high-risk patients and begin prophylactic treatment as early as possible. According to the current standard for monitoring cardiac function cardiotoxicity is usually detected only once a functional impairment has already occurred, thus precluding any chance of prevention. The measurement of cardio-specific biomarkers can be a valid diagnostic tool for the early identification, assessment and monitoring of cardiotoxicity. The role of Troponin I in identifying patients with subclinicalcardiotoxicity and their subsequent treatment with angiotensin- converting enzyme inhibitors to prevent left ventricular ejection fraction (LVEF) reduction and cardiac events, is emerging as an effective strategy against these complications. When this approach is not feasible, a complete LVEF recovery and a reduction in cardiac events may be achieved if left ventricular dysfunction (LVD) is detected early and the patient promptly treated with angiotensin-converting enzyme inhibitors, possibly in combination with beta-blocking agents.Giulia BacchianiDaniela CardinaleSouth African Heart Associationarticlecardiac toxicitybiomarkersearly prophylactic treatmentcancerchemotherapyDiseases of the circulatory (Cardiovascular) systemRC666-701ENSA Heart Journal, Vol 9, Iss 4, Pp 250-262 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiac toxicity biomarkers early prophylactic treatment cancer chemotherapy Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	cardiac toxicity biomarkers early prophylactic treatment cancer chemotherapy Diseases of the circulatory (Cardiovascular) system RC666-701 Giulia Bacchiani Daniela Cardinale Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
description	Cardiac toxicity induced by anticancer therapy is of considerable concern for, once it develops, it may compromise the clinical effectiveness of treatment independent of the oncologic prognosis. The main strategy to minimize cardiotoxicity is to detect high-risk patients and begin prophylactic treatment as early as possible. According to the current standard for monitoring cardiac function cardiotoxicity is usually detected only once a functional impairment has already occurred, thus precluding any chance of prevention. The measurement of cardio-specific biomarkers can be a valid diagnostic tool for the early identification, assessment and monitoring of cardiotoxicity. The role of Troponin I in identifying patients with subclinicalcardiotoxicity and their subsequent treatment with angiotensin- converting enzyme inhibitors to prevent left ventricular ejection fraction (LVEF) reduction and cardiac events, is emerging as an effective strategy against these complications. When this approach is not feasible, a complete LVEF recovery and a reduction in cardiac events may be achieved if left ventricular dysfunction (LVD) is detected early and the patient promptly treated with angiotensin-converting enzyme inhibitors, possibly in combination with beta-blocking agents.
format	article
author	Giulia Bacchiani Daniela Cardinale
author_facet	Giulia Bacchiani Daniela Cardinale
author_sort	Giulia Bacchiani
title	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
title_short	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
title_full	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
title_fullStr	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
title_full_unstemmed	Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
title_sort	using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
publisher	South African Heart Association
publishDate	2017
url	https://doaj.org/article/12f648ef49e640cfa4136c500eecbf4d
work_keys_str_mv	AT giuliabacchiani usingbiomarkersandearlyprophylactictreatmenttopreventcardiotoxicityincancerpatientsonchemotherapy AT danielacardinale usingbiomarkersandearlyprophylactictreatmenttopreventcardiotoxicityincancerpatientsonchemotherapy
_version_	1718407328792838144

Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy

Ejemplares similares